← Leaderboards
Caroline Nebhan
Vanderbilt University
$258,460
Attributed
$258,460
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $71.4K · FY2013–21$100K$75K$50K$25K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$258,460 · 2
By mechanism
F32$129,630 · 1
F30$128,830 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Ann Richmond$15,857,391
- Nikki Cheng$4,462,144
- Alfred L George$44,065,377
- Jeffrey R Balser$3,534,590
- Raymond Nelson Dubois$22,706,669
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantClinical TrialsResistanceSamplingMutationCellsMediatingPreventTumorCell LineBaseResponseTargeted TreatmentCancer CellBindingEnvironmentDrug ResistanceDrug-SensitiveEpidermal Growth Factor ReceptorCell GrowthComplexCytoskeletal ProteinsCell AdhesionBiological Process
Grant awards (5)
Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma$58,200
F32 · FY2021 · CA · contact PI
Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma$71,430
F32 · FY2020 · CA · contact PI
The role of NF2 in Acquired Resistance to Targeted EGFR Inhibition in Lung Cancer$33,478
F30 · FY2016 · CA · contact PI
The role of NF2 in Acquired Resistance to Targeted EGFR Inhibition in Lung Cancer$48,120
F30 · FY2015 · CA · contact PI
The role of NF2 in Acquired Resistance to Targeted EGFR Inhibition in Lung Cancer$47,232
F30 · FY2013 · CA · contact PI